MedPath

Methotrexate Polyglutamate Measurements in Patients With Inflammatory Bowel Disease

Suspended
Conditions
IBD
Registration Number
NCT04205734
Lead Sponsor
Boston Children's Hospital
Brief Summary

There are currently no serum levels to help guide appropriate methotrexate therapy. Data from this study will assess the correlation between dosing and whole blood methotrexate(MTX) polyglutamate measurements in children and adolescents with IBD.

Detailed Description

This is a cross-sectional study design. Subjects will be requested to provide one blood sample to be collected during the conduct of their routine clinical care. Data related to the diagnosis and interval assessment of enrolled subjects will also be collected.

Recruitment & Eligibility

Status
SUSPENDED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • IBD
  • Methotrexate Therapy
Exclusion Criteria
  • Inability to provide relevant samples

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Methotrexate Polyglutamate LevelSamples will collected within 16 weeks of consent.

Measurement of Methotrexate Polyglutamate Levels

Secondary Outcome Measures
NameTimeMethod
The correlation between Methotrexate Polyglutamate Levels and Clinical HistorySamples will collected within 16 weeks of consent.

Do Methotrexate Polyglutamate Levels Predict Clinical Outcome as Measured by Disease Activity Indices, including PUCAI for ulcerative colitis and PCDAI for patients with Crohn Disease

The correlation between Methotrexate Polyglutamate Levels and Lab ParametersSamples will collected within 16 weeks of consent.

Compare the relationship between Methotrexate Polyglutamage levels and ESR,CRP, Hemoglobin, and Albumin

Trial Locations

Locations (1)

Boston Children's Hospital

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath